Related Experiment Video

Updated: Jun 6, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Benefits of prestroke use of angiotensin type 1 receptor blockers on ischemic stroke severity

Nobukazu Miyamoto1, Yasutaka Tanaka, Yuji Ueno

  • 1Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|November 25, 2010
PubMed

Insights

Angiotensin type 1 receptor blockers (ARBs) show promise in improving outcomes for patients who have experienced an ischemic stroke. Pretreatment with ARBs was associated with better functional status post-stroke.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Antihypertensive agents' stroke prevention benefits are linked to blood pressure reduction.
  • The role of specific antihypertensive classes, like ARBs, in stroke outcomes requires further investigation.

Purpose of the Study:

  • To evaluate the benefits of angiotensin type 1 receptor blockers (ARBs) in patients prior to ischemic stroke onset.
  • To assess the association between ARB use and patient outcomes after ischemic stroke.

Main Methods:

  • Retrospective study using hospital discharge data from April 2007 to March 2009.
  • Analysis of demographic and clinical characteristics, including functional status assessed by modified Rankin Scale (mRS) and Barthel Index (BI).

Main Results:

  • 151 patients were analyzed; ARB users had different co-medication profiles and higher rates of diabetes.
  • Logistic regression revealed pretreatment with ARBs was significantly associated with better outcomes (mRS ≤ 2, P < .014) and functional status (BI > 75, P < .020).
  • Older age and large artery atherosclerosis were associated with severe outcomes.

Conclusions:

  • The findings support the use of Angiotensin type 1 receptor blockers (ARBs) in hypertensive patients.
  • ARBs may offer additional benefits beyond blood pressure control in stroke prevention and recovery.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...